GenEdit is sailing toward the clinic with a new name and fresh funding. | GenEdit is sailing toward the clinic with a new name and fresh funding. Rebranded as BreezeBio, the biotech has raised $60 ...
Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 | When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing ...
In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...
Following the release of the first swath of results from a pharma- and he | In developing media plans to reach the GLP-1-interested consumer, audio advertising may represent a “blind spot,” according ...
Novartis is wasting little time sketching out the radiopharmaceutical details of its $23 billion U.S. investment push. | Novartis is wasting little time sketching out the radiopharmaceutical details ...
A coalition of 15 states is filing a lawsuit against Robert F. Kennedy Jr. | A coalition of 15 states is filing a lawsuit against Robert F. Kennedy Jr. and the Centers for Disease Control and ...
Sanofi has kicked off its preparations for the 2026 World Cup by becoming an official backer of Boston’s involvement in the soccer showcase. | Sanofi has kicked off its preparations for the 2026 World ...
AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty ...
Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. | ...
The agreement ends litigation between the Swiss company and the estate of Henrietta Lacks, which filed a lawsuit in federal court in Baltimore against Novartis and Viatris in August 2024. The family ...
Still, broad uptake has long been an uphill battle for the gene therapy as it competes with a variety of treatments including, Roche’s blockbuster Hemlibra, Sanofi’s newer sales driver Altuviiio and ...
Roche’s autoimmune drug Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder (NMOSD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results